Loading...
EQL Pharma Community
OM:EQL Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
Community Investing Ideas
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q1 update Strong revenue growth yoy 45% exceding expectations. Strong EPS of 178%, however easy comps should be noted.Read more
2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
MA
SEK 86.37
38.6% undervalued intrinsic discount
Mandelman Fair Value
Revenue growth
21.49% p.a.
Profit Margin
15%
Future PE
25x
Share price in 2029
SEK 115.56
European Market Expansion And Pipeline Development Will Unlock Potential
Key Takeaways Enlarged European market reach and a deep pipeline of generics underpin prospects for robust, sustained revenue and margin growth. Operational efficiencies, disciplined acquisitions, and targeted R&D boost earnings quality and position EQL Pharma for enhanced resilience and market value.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 80
33.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
32.63% p.a.
Profit Margin
16.02%
Future PE
18.66x
Share price in 2028
SEK 89.88
